268 related articles for article (PubMed ID: 29250254)
1. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation.
Lavoie K; Turgeon MH; Brais C; Larochelle J; Blais L; Farand P; Letemplier G; Perreault S; Beauchesne MF
J Atr Fibrillation; 2016 Dec; 9(4):1478. PubMed ID: 29250254
[TBL] [Abstract][Full Text] [Related]
2. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study.
Miyazaki M; Matsuo K; Uchiyama M; Nakamura Y; Sakamoto Y; Misaki M; Tokura K; Jimi S; Okamura K; Adachi S; Yamamoto T; Shirai K; Urata H; Imakyure O
J Pharm Health Care Sci; 2020; 6():2. PubMed ID: 32071730
[TBL] [Abstract][Full Text] [Related]
3. Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over.
Cavillon Decaestecker M; Ferret L; Decaestecker K; Gautier S; Verdun S; Tsogli ES
Drugs Aging; 2021 Oct; 38(10):939-950. PubMed ID: 34486094
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF.
Guenoun M; Cohen S; Villaceque M; Sharareh A; Schwartz J; Hoffman O; Dib JC; Ouazana L; Assouline S; Parrens E; Garban T; Pradeau V; Guedj-Meynier D; Lequeux B; Cohen C; Durand P; Dievart F; Dhanjal TS; Sabouret P; Lellouche N
Europace; 2023 Oct; 25(10):. PubMed ID: 37801642
[TBL] [Abstract][Full Text] [Related]
5. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
[TBL] [Abstract][Full Text] [Related]
6. Inappropriate direct oral anticoagulant prescriptions in patients with non-valvular atrial fibrillation: cross-sectional analysis of the French CACAO cohort study in primary care.
Ferrat E; Fabre J; Galletout P; Boutin E; Le Breton J; Renard V; Frappé P; Bastuji-Garin S
Br J Gen Pract; 2021; 71(703):e134-e139. PubMed ID: 33495204
[TBL] [Abstract][Full Text] [Related]
7. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
Elewa H; El-Makaty H; Ali Z
J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):155-161. PubMed ID: 28978236
[TBL] [Abstract][Full Text] [Related]
8. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
Li RJ; Caughey GE; Shakib S
J Thromb Thrombolysis; 2022 Feb; 53(2):425-435. PubMed ID: 34302286
[TBL] [Abstract][Full Text] [Related]
9. Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing.
Moudallel S; Steurbaut S; Cornu P; Dupont A
Front Pharmacol; 2018; 9():1220. PubMed ID: 30425641
[No Abstract] [Full Text] [Related]
10. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation.
Kuo LT; Lin SJ; Wu VC; Chang JJ; Chu PH; Lin YS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211011374. PubMed ID: 33995605
[TBL] [Abstract][Full Text] [Related]
12. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
13. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Lau WCY; Torre CO; Man KKC; Stewart HM; Seager S; Van Zandt M; Reich C; Li J; Brewster J; Lip GYH; Hingorani AD; Wei L; Wong ICK
Ann Intern Med; 2022 Nov; 175(11):1515-1524. PubMed ID: 36315950
[TBL] [Abstract][Full Text] [Related]
15. Eight-Year Trends in Direct-Acting Oral Anticoagulant Dosing, Based on Age and Kidney Function, in Patients With Atrial Fibrillation.
Bezabhe WM; Bereznicki LR; Radford J; Wimmer BC; Salahudeen MS; Peterson GM
J Patient Saf; 2022 Jun; 18(4):337-341. PubMed ID: 35617592
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation.
Qian Y; Zhang J; Li J; Weng Z
PLoS One; 2021; 16(11):e0259199. PubMed ID: 34762667
[TBL] [Abstract][Full Text] [Related]
17. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
[TBL] [Abstract][Full Text] [Related]
18. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
[TBL] [Abstract][Full Text] [Related]
19. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.
Fanning L; Ilomäki J; Bell JS; Dārziņš P
Eur J Clin Pharmacol; 2017 Nov; 73(11):1427-1436. PubMed ID: 28752255
[TBL] [Abstract][Full Text] [Related]
20. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
Jansson M; Själander S; Sjögren V; Björck F; Renlund H; Norrving B; Själander A
J Thromb Thrombolysis; 2023 Apr; 55(3):415-425. PubMed ID: 36607464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
